These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29289981)

  • 1. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
    Wei F; Shin D; Cai X
    Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
    Jia Y; Lacouture ME; Su X; Wu S
    J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.
    Qi WX; Sun YJ; Shen Z; Yao Y
    J Chemother; 2014 Dec; 26(6):359-68. PubMed ID: 24621163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
    Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
    Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.
    Petrelli F; Borgonovo K; Cabiddu M; Coinu A; Ghilardi M; Lonati V; Barni S
    Br J Dermatol; 2016 Dec; 175(6):1166-1174. PubMed ID: 27214209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
    Drucker AM; Wu S; Dang CT; Lacouture ME
    Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Zhang X; Ran YG; Wang KJ
    Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
    Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
    Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
    N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.